Sol-Gel Technologies’ work to expand the treatment options for patients with the skin condition rosacea has paid off, with the FDA approving a product based on its microencapsulation technology.
NESS ZIONA, Israel, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. , a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a Phase-3 clinical ...
LONDON--(BUSINESS WIRE)--The sol-gel coatings market is expected to grow by USD 2.63 billion during 2020-2024, according to Technavio. The report offers a detailed analysis of the impact of COVID-19 ...
The under-the-radar pharma company might have one of the industry's more promising approaches to dermatology treatments. But the narrative may have changed. Sol-Gel delivered positive late-stage ...
NESS ZIONA, Israel & LAUSANNE, Switzerland--(BUSINESS WIRE)--Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company, and Galderma, the world’s largest independent dermatology ...
Sol-Gel Technologies reports increased Q1 revenue and expenses, with a net loss of $8.8 million compared to $6.3 million in 2024. Sol-Gel Technologies, Ltd., a clinical-stage dermatology company, ...
Sol-Gel Technologies (SLGL) has released an update. Sol-Gel Technologies announced a significant improvement in its financial performance for Q3 2024, with a reduction in net losses and an increase in ...
Just because a business does not make any money, does not mean that the stock will go down. For example, Sol-Gel Technologies (NASDAQ:SLGL) shareholders have done very well over the last year, with ...
Active investing isn't easy, but for those that do it, the aim is to find the best companies to buy, and to profit handsomely. When you find (and hold) a big winner, you can markedly improve your ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results